Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Blood Adv. 2023 Feb 28;7(4):644-648. doi: 10.1182/bloodadvances.2022007625.

Authors

Suzette Girgis¹, Shun Xin Wang Lin¹, Kodandaram Pillarisetti¹, Raluca Verona¹, Diego Vieyra¹, Tineke Casneuf², Damien Fink¹, Xin Miao¹, Yang Chen¹, Tara Stephenson¹, Arnob Banerjee¹, Brandi W Hilder¹, Jeffery Russell¹, Jeffrey Infante¹, Yusri Elsayed¹, Jennifer Smit¹, Jenna D Goldberg¹

Affiliations

¹ Janssen Research & Development, LLC, Spring House, PA.
² Janssen Research & Development, LLC, Beerse, Belgium.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents*
B-Cell Maturation Antigen
Humans
Immunotherapy, Adoptive
Multiple Myeloma*
Neoplasms, Plasma Cell*

Substances

B-Cell Maturation Antigen
Antineoplastic Agents